SCHEMBL6484529

SCHEMBL6484529

CC(C)(C)OC(=O)N1CCN(CCc2nnnn2C(c2ccccc2)(c2ccccc2)c2ccccc2)CC1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.46
CHRM4 P08173 1/20 0.46
CHRM1 P11229 1/20 0.46
CHRM3 P20309 1/20 0.46
ACKR3 P25106 3/20 0.43
SIGMAR1 Q99720 2/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
ESR2 Q92731 1/20 0.40
TERT O14746 1/20 0.40
ABCB1 P08183 1/20 0.39
CKS1B P61024 1/20 0.39
SKP1 P63208 1/20 0.39
SKP2 Q13309 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
NAMPT P43490 1/20 0.39
CCR5 P51681 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6476320 0.90 LMNA (0.47) CHRM2CHRM4CHRM1CHRM3ACKR3
SCHEMBL6482957 0.85 KDM4E (0.49) GPR119
SCHEMBL6485532 0.82 KDM4E (0.50) MAPTGPR119NAMPT
SCHEMBL3712707 0.76 MEN1 (0.59) CHRM2CHRM4CHRM1CHRM3ACKR3
SCHEMBL7181950 0.76 ACKR3 (0.45) CHRM2CHRM4CHRM1CHRM3ACKR3
SCHEMBL2867370 0.75 GPR119 (0.53) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL7986044 0.72 SIGMAR1 (0.55) CHRM2CHRM4CHRM1CHRM3ACKR3
SCHEMBL7971782 0.72 SIGMAR1 (0.69) ACKR3SIGMAR1
SCHEMBL9933431 0.72 FAAH (0.47) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL31093166 0.72 KMT2A (0.57) CHRM2CHRM4CHRM1CHRM3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1312153-C Pyrrolopyrimidinone derivatives, process for their preparation and their use SK CHEMICALS CO LTD (KR) 2007-04-25 CN disclosed
US-6962911-B2 Pyrrolopyrimidinone derivatives, process of preparation and use SK CHEMICALS CO., LTD. (KR) 2005-11-08 US disclosed
EP-1257553-B1 PYRROLOPYRIMIDINONE DERIVATIVES, PROCESS OF PREPARATION AND USE SK CHEMICALS CO LTD (KR) 2004-05-26 EP disclosed
US-20030171361-A1 Pyrrolopyrimidinone derivatives, process of preparation and use SK CHEMICALS CO., LTD. (KR) 2003-09-11 US disclosed
CN-1422271-A Pyrrolopyrimidinone derivatives, process for their preparation and their use SK CHEMICALS CO LTD (KR) 2003-06-04 CN disclosed
EP-1257553-A1 PYRROLOPYRIMIDINONE DERIVATIVES, PROCESS OF PREPARATION AND USE SK Chemicals Co., Ltd. (KR) 2002-11-20 EP disclosed
WO-2001060825-A1 PYRROLOPYRIMIDINONE DERIVATIVES, PROCESS OF PREPARATION AND USE SK CHEMICALS CO., LTD. (KR) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171361-A1 Pyrrolopyrimidinone derivatives, process of preparation and use CYP2C19, DHPS, SDHA CHRM2 4170/4885CHRM4 4352/4885CHRM1 3482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.